Drug Profile
Research programme: inflammation therapeutics - Evotec SE
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Evotec SE
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MAP-kinase-activated kinase 2 inhibitors; Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 21 May 2007 Inflammation programme is available for licensing worldwide (http://www.evotec.com)
- 21 May 2007 Early research in Inflammation in Germany (unspecified route)